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Escherichia coli, one of the most common pathogens causing urinary tract infections, has
shown increased resistance to commonly used antibiotics. In this study we analyzed the
p-lactamase profiles of38 inhibitor-resistant E. coli isolates obtained from public
hospitals at three different levels of healthcare in KwaZulu-Natal, selected on the basis of
their resistance profiles to the three antibioticlinhibitor combinations, viz., amoxicillinJ
c1avulanate, ampicillin/ sulbactam and piperacillin/ tazobactam. The isolates were
subjected to MIC determinations, IEF analysis, plasmid profile analysis, PCR of the
different p-Iactamase genes and sequencing thereof to detect the possible mechanism/s of
resistance. A range of p-lactamases including two novel inhibitor-resistant TEM ~­
lactamases, TEM-145 and TEM-146 were detected in two isolates whilst a novel
plasmid-mediated AmpC-type ~-Iactamase, CMY-20 was detected in three isolates. Other
p-lactamases included OXA-l, TEM-55, SHV-~, CTX-M-l and TEM-1. Changes were
detected in the chromosomal AmpC promoter/attenuator regions in one isolate. Diverse
~-lactamase genes and plasmid profiles inferred extensive mobilization of ~-lactamase




I thank God for giving me the strength and courage to underta e this study
This study would not have been possible without the assistance, love and support of
many people and my heartfelt thanks goes to:
My supervisor, Prof Sabiha Essack, thanks for the assistance, :mpport, constructive
criticism and guidance throughout this study. I really appreciated it.
My co-supervisor, Prof Willem Sturm, for the guidance and constructive criticism
My colleague and fellow student, Sara Govinden for all the help, support, technical
assistance and friendship.
My colleagues in the Discipline of Pharmacy, especially ProfThiru Govender, Les
Murugan, Aasha Bagwandeen and Vassie Naidoo, thanks for the love, support, friendship
and guidance.



















1.3.3.1. CHROMOSOMAL AMPC ~-LACTAMASES
1.3.3.2. PLASMID-MEDIATED AMPC ~-LACTAMASES











































~-Iactam antibiotics, embracing penicillins with or without ~-Iactamase inhibitors,
cephalosporins, cephamycins, oxycephamycins, monobactams, carbapenems, penems and
carbacephems, are the most frequently prescribed antimicrobial agents in clinical practice
(Canica et al., 1998; Edwards & Betts, 2000). Starting with the discovery of
benzylpenicillin in 1928 and its first clinical use in 1940, numl~rous natural and synthetic
compounds have been described based upon the active structure of penicillin, i.e., the ~­
lactam ring. The penicillins and cephalosporins which are based on 6-aminopenicillanic
acid and 7-aminocephalosporanic acid respectively, are the two classical ~-Iactam
families. In addition, various non-classical ~-Iactams have been developed, including
monocyclics and carbapenems. The success of I-I-Iactams may be attributed to low
toxicity and the availability of so many derivatives (Livermon: & Williams, 1996).
Antibiotic resistant pathogenic bacteria has become a major problem, especially amongst
Gram-negative bacteria causing hospital infections (Silva et al., 1999; Wiener et a/.,
1999). Resistance has been caused by the widespread use, and sometimes abuse, of
broad-spectrum antibiotics not only in medical practice (Gunseren et a/. 1999; Matagne
et al., 1999) but also in animal husbandry (Matagne et a/., 1999). The three main
mechanisms to antibiotic resistance are:
•
•
Decreased permeability of the drug into the cell by the loss or alteration of outer
membrane proteins (Omps) (Heritage et al., 1999; Silva et a/., 1999).
Decreased affinity of the target penicillin binding proteins (Silva et a/., 1999;
Edwards & Betts, 2000).
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• Production of ~-lactamasesthat hydrolyze the ~-lactarn bond in the antibiotics,
thus destroying its functionality (Heritage et al., 1999; Kuzin et al., 1999; Silva et
al., 1999; Vakulenko et al., 1998). These are either chromosomal enzymes that
can be over-expressed (derepressed) or encoded by plasmids (Edwards & Betts,
2000).
The most common mechanism for resistance in Gram-negative bacteria is the expression
of~-lactamases(Pitoutetal., 1998; Silva et al., 1999; Vakulenkoetal., 1998). Two
strategies have been devised to counter the resistance of bacteria, viz., the development of
new ~-lactam drugs that are inherently less susceptible to ~-lactamases and the
combination of mechanism based inactivators and a penicillin (Chaibi et al., 1999).
1.2. ESCHERICHIA COLI
Escherichia coli belongs to the family Enterobacteriaceae, which is a large,
heterogeneous group of Gram-negative rods. Their natural habitat is the intestinal tract of
humans and animals (Brooks et al., 2001). E. coli, one of the most frequently isolated
nosocomial pathogens (Yagi et al., 1997; Clarke et al., 2003) is also the most common
cause of urinary tract infections (Brooks et al., 2001). Other diseases caused include
meningitis, septicaemia, wound infections, pneumonia, dysentery and diarrhea (Bhatia &
Ichhpujani, 2004). E. coli isolates causing diarrhea are classified by the characteristics of
their virulence properties into the following classes, viz., enteropathogenic E. coli
(EPEC) (causes diarrhea in infants especially in developing countries), enterotoxigenic E.
coli (ETEC) (common cause of'travelers' diarrhea' and an important cause of diarrhea in
infants in developing countries), enterohaemorrhagic E. coli (EHEC) (associated with
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haemorrhagic colitis, a severe form of diarrhea), enteroinvasive E. coli (EIEC) (similar to
shigellosis) and enteroaggregative E. coli (EAEC) (causes acute and chronic diarrhea)
(Brooks et al., 2001).
1.3. P-LACTAMASES
Analysis of known ~-Iactamase sequences has resulted in them being divided according
to their amino acid sequences into four classes, designated A to D (Poirel et al., 1999).
Class A ~-Iactamases are of importance since they exhibit highly variable substrate
profiles and are generally encoded by plasmids, which facilitate transfer between cells
(Ibuka et al., 1999). The class A enzymes which were originally designated penicillinases
because they hydrolyzed penicillins with occasional weak activity towards cephems,
include many of the plasmid-mediated enzymes from Gram-negative bacteria and
chromosomal enzymes from Gram-positive bacteria. Class B fI-lactamases are the
metalloenzymes and exhibit a very large spectnlm of activity. These plasmid-encoded
enzymes are not sensitive to the common ~-Iactamase inactivators but always hydrolyzed
carbapenems, a family of ~-Iactams that is not susceptible to most class A, C and D
enzymes. Class C ~-Iactamases include the chromosomal cephalosporinases of Gram-
negative bacteria and confer resistance not only to classical compounds such as
ampicillin and cephalothin but also to third generation cephalosporins (Matagne et al.,
1999). Class D ~-Iactamases are unique enzymes with the abihty to hydrolyze oxacillin, a
semi-synthetic penicillin stable to many ~-Iactamases (Kuzin et aI., 1999).
4
Amongst the four ~-Iactamase classes, the class A enzymes are the most frequently
encountered in clinical isolates because of plasmid-mediated selection and transfer in
response to the introduction of new ~-Iactams. "Extended-spectrum" class A ~­
lactamases are variants of a parental type and have 1-5 amino acid substitutions for better
hydrolysis of second and third generation cephalosporins (Rasheed et aI., 1997;
Gniadkowski et al., 1998; Kuzin et aI., 1999).
The following is a synopsis of~-Iactamases encountered in E. coli, a species traditionally
susceptible to most ~-Iactam antibiotics:
1.3.1. INHIBITOR-RESISTANT P-LACTAMASES (ffiTs)
~-Iactamase inhibitors protect the ~-Iactams from hydrolysis by the ~-Iactamaseswhen
the inhibitors are used in combination with ~-Iactams. Three ~-Iactamase inhibitors,
clavulanic acid, sulbactam and tazobactam, are available for clinical use in combination
with a number ofpenicillins (Vakulenko et al., 1998; Doi et aI., 2004). The inhibitors
mainly target Ambler class A ~-Iactamases and inactivate their active site serines, thus
potentiating the actions of ~-Iactamase-sensitivecompounds (Doi et aI., 2004).
Amoxicillin/clavulanate is a ~-Iactam-~-Iactamase inhibitor combination that has
antimicrobial activity against Gram-positive, Gram-negative and anaerobic organisms,
but resistance has emerged with increasing use of this antimicrobial agent. (Kaye et al.,
2004). Resistance to amoxicillin/clavulanate appeared first in Escherichia coli isolates,
then in other species of enterobacteria (Speldooren et al., 1998) and could be attributed to
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the hyperproduction of the chromosomal class C ~-lactamase, hyperproduction ofTEM-1
~-lactamase,production of oxaci llinases, the production of TEM-derived enzymes whose
~-lactamases activities are longer inhibited clavulanate (IRTs) and modification of the
outer membrane proteins (Henquell et al., 1994; Sirot et aI., 1994; Speldooren et aI.,
1998; Chaibi et aI., 1999; Leflon-Guibert et aI., 2000; Miro et aI., 2002).
IRT ~-lactamases have been isolated since the beginning of the 1990s and are mostly
produced by strains ofE. coli but also by clinical isolates ofKlebsiella spp and Proteus
mirabilis. These enzymes confer resistance to penicillins and their combinations with ~­
lactamase inhibitors. IRT variants are derivatives ofTEM-1 and TEM-2 ~-lactamases and
differ from the parental enzymes by various combinations of amino acid substitutions
(Goussard & Courvalin, 1999). Mutations at amino acid positions 69, 130,244,275 and
276 (according to Ambler's numbering) that have been shown or postulated to play a role
in determining resistance to inhibitors (Alonso et aI., 2002; Vakulenko & Golemi, 2002).
These substitutions decrease the affinity for ~-Iactams and alter the way in which the
enzymes interact with suicide inactivators (Alonso et aI., 2002).
1.3.2. EXTENDED-SPECTRUM p-LACTAMASES (ESBLs)
In Gram-negative pathogens, ~-lactamases remain the most common cause of ~-lactam
resistance, and their increasing prevalence, as well as their extensive evolution, appears
to be directly linked to the clinical use of sub-classes of ~-lactams (pitout et aI., 2005).
The introduction of expanded-spectrum cephalosporins in clinical practice represented a
major breakthrough for the treatment of nosocomial infections caused by
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Enterobacteriaceae producing broad-spectrum ~-lactamases such as the widespread TEM-
1, TEM-2 and SHV-1 enzymes (Perilli et ai, 2002). However, the extensive use of these
drugs was rapidly followed by the emergence of resistance (Perilli et aI., 2002;
Graffunder et aI., 2005). ESBLs are able to hydrolyse broad-spectrum cephalosporins and
monobactams which are stable to classic TEM and SHY enzymes (Jacoby & Han, 1996;
Yang et aI., 1998; Girlich et aI., 2001; Lee et ai, 2004; Brifias et aI., 2005), as well as to
the older penicillins and cephalosporins (Jacoby & Han, 1996) while remaining
susceptible to ~-lactamase inhibitor combinations, cephamycins and carbapenems
(Graffunder et aI., 2005; Pitout et al., 2005).
The genes encoding extended-spectrum ~-lactamases (ESBLs) are usually carried by
multi-drug resistance plasmids which are readily transferable and which may carry genes
encoding resistance to other antibiotics such as aminoglycosides (Yang et aI., 1998; Silva
et al., 1999; Mulvey et ai., 2004). These plasmids strongly facilitate the spread of
enzymes among strains of many species of Gram-negative bacteria but Klebsiella
pneumoniae and E. coli remain the most frequently reported producers ofESBLs. Since
the first ESBL-expressing isolate was reported in a K. pneumoniae isolate in Germany in
1983 many kinds ofESBLs have been characterized and described. (Gniadkowski et aI.,
1998; Girlich et aI., 2001; Mulvey et ai., 2004) and infections caused by ESBL-
producing members of the family Enterobacteriaceae have rapidly increased (Girlich et
ai., 2001).
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ESBLs have been described world wide and are a major cause of nosocomial infections
associated with high mortality (Gray et al., 2006). They exhibit high degrees of diversity
in their structures and activities and several families have been identified on the basis of
their evolutionary and/or functional similarities (Gniadkowski et a/., 1998). Most ESBLs
are derived from the classical TEM-l, TEM-2 and SHV-l enzymes, by amino acid
substitutions in their sequences (Spanu et al., 2002; Brinas et a/., 2005; Delmas et a/.,
2005; Robin et a/., 2006), which extend the substrate specificities to extended-spectrum
cephalosporins (Delmas et a/., 2005).
1.3.2.1. TEM
The TEM family ofESBLs constitutes the largest and widely disseminated group of these
enzymes in nosocomial isolates ofEnterobacteriaceae worldwide and their dissemination
continues to compromise antimicrobial chemotherapy (Perilli et a/., 2002; Baraniak et a/.,
2005).
TEM-l is able to hydrolyze penicillins and cephalosporins such as cephalothin. TEM-2
differs from TEM-l by substitution of lysine for glutamine at position 37 «Philippon et
a/., 1989) but its substrate profile remains very similar to that of TEM-l (Bradford,
2001). The first outbreak of a TEM-derived ESBL, TEM-3, was reported in 1989 in
France (Morris et al., 2003).
The TEM-type ESBLs show a reduced catalytic efficiency towards penicillins and a
broadened spectrum towards expanded-spectrum cephalosporins (perilli et a/., 2002). The
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amino acid substitutions that occur within the TEM-enzyme occur at a limited number of
positions. The combinations of the amino acid changes results in alterations in the
phenotype of the enzyme (Bradford, 2001). In TEM-type ESBLs, the most significant
amino acid substitutions occur at positions 104 (glutamic acid to lysine), 164 (arginine to
serine or histidine), 238 (glycine to serine) and 240 (gluatamic acid to lysine) (Bradford,
2001; Baraniak et aI., 2005; Ikryannikova et aI., 2008). When the glutamic acid at
position 104 is substituted by lysine, the long side chain oflysine could interact with the
carboxylic acid group of oxyimino-cephalosporins such as ceftazidime. This electrostatic
attraction would increase the initial binding, possibly increasing the ~-Iactamase affinity
(lowering the Km) and increasing Vmax values, but only in conjunction with other
mutations such as Arg-164 (Knox, 1995; Petit et a\., 1995). The high catalytic efficiency
against oxyimino-~-Iactams such as ceftazidime and cefotaxime is linked to the
substitution of arginine at position 164 and glycine at position 238 (Maveyraud et aI.,
1996). The Arg-164-Ser substitution reported in TEM-12 allows this enzyme to
hydrolyze ceftazidime more effectively than cefotaxime (Morosini et aI., 1995). X-ray
structural studies have shown that in the TEM-I enzyme, at position 164, the arginine is
below the binding site of the omega loop (positions 162-179) that contains the catalytic
Glu-166 and the guanidium side chain is strongly linked by electrostatic interaction and
hydrogen bonds to Asp-179 which lies across the neck of the loop. Substitution of the
arginine at position 164 is one of the most common substitutions observed in TEM
ESBLs. When the arginine is replaced by either serine or histamine, it results in one less
hydrogen bond donor which can weaken the linkage across the neck of the omega loop.
This allows for more flexibility in the loop and this creates more space for bulky ~-Iactam
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constituents (Knox, 1995). Site-directed mutagenesis studies showed improved kcatl Km
for oxyiminocephalosporins such as ceftazidime and cefotaxime (Sowek et al., 1991).
Substitution of the glycine at position 238 with serine extends the substrate spectrum of
the TEM-enzyme to include ceftazidime (Maveyraud et aI., 1996). The side chain of the
amino acid at position 238 is on the inner side of the B3 ~-strand. It lies very close to the
side chain of the amino acid at position 69; therefore there is a correlation between the
sizes of the side chains of each amino acid. [fthe side chain of both the amino acids at
positions 69 and 238 are large, there is crowding and this may displace the B3 ~-strand
outward. This results in the lower portion of the binding site becoming slightly expanded,
resulting in cephalosporins with rigid branched acyl-amido suhstituents being able to
form hydrogen bonds with residue 237. This could result in lower Km values. When the
glutamic acid is replaced by lysine at position 240, the side chain of lysine is able to form
an electrostatic bond with the carboxylic acid group of the oxyimino cephalosporin. This
results in hydrolysis of ceftazidime and aztreonam. TEM-24 has the amino acid at
position 104 and 240 substituted with lysine and this enzyme has the highest Vmax for
ceftazidime (Knox, 1995).
1.3.2.2. SHY
SHY-type ~-lactamases are one of the most clinically significant families of plasmid-
mediated ~-lactamases (Kim & Lee, 2000) and may be found amongst many members of
the family Enterobacteriaceae (Heritage et al.. 1999). SHV-1 is a narrow spectrum ~­
lactamase with activity against penicillins (Ma et aI., 2005). Point mutations of the genes
encoding for SHY-type ~-lactamases can change their profile of activity to include most
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~-lactams with the exception of cephamycins and carbapenem) (Kim & Lee, 2000). The
first ESBL, derived from SHV-l was reported in 1983 and was named SHY-2 (Morris et
aI., 2003). The serine at amino acid position 238 was replaced by glycine in SHV-l and
this amino acid allowed for more efficient hydrolysis of cefotaxime than ceftazidime
(Kim & Lee, 2000; Hujer et aI., 2002). The amino acid substitution at position 238 causes
displacement of the B3 ~-strand in the SHY-enzyme and this causes a slight opening of
the active site, thus allowing entrance of the bulkier oxyimino cephalosporins (Randegger
et aI., 2000). In SHY-5 there is an amino acid change at position from glutamic acid
(SHY-2) to lysine (SHV-5) and this mutation was found to increase the hydrolytic
activity of this enzyme against ceftazidime and aztreonam rather than cefotaxime
(Bradford et aI., 1995; Kim & Lee, 2000). Position 240 of the SHY-enzyme is at the
bottom of the ~-pleated sheet and when the lysine at this position is replaced with a
negatively charged amino acid such as glutamic acid, it attracts and binds the terminal
carboxyl group on the long oxyimino side chains of ceftazidime and aztreonam (Heritage
et aI., 1999).
1.3.2.3. CTX-M
The emergence of new enzyme groups that have a typical ESBL resistance phenotype but
that are non-TEM and non-SHY derivatives have been reported. CTX-M-type ~­
lactamases constitute a group of enzymes encoded by transferable plasmids (Eckert et aI.,
2004). This family of plasmid-mediated ESBLs has been classified in Ambler class A
(Bonnet et aI., 2000). They are capable of hydrolyzing broad-spectrum cephalosporins
(Eckert et aI., 2004) and are inhibited by clavulanic acid, sulbactam and tazobactam (Ma
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et aI., 2002; Eckert et aI., 2004). CTX-M p-Iacatamases have emerged in many countries
of the world (Edelstein et al., 2003; Cartelle et al., 2004). Since the first report ofCTX-M
ESBL from a strain ofE. coli in 1989, the CTX-M family ofESBLs has spread in several
countries in Europe, Latin America, Africa and Asia (Kiratisin et aI., 2007). The first
organisms producing p-Iactamases of this type were identified both as single and
epidemic clinical isolates in distant geographic regions (Germany, France, South
America) in the early 1990s (Edelstein et aI, 2003).
CTX-M enzymes can be subclassified by amino acid sequence similarities into various
clusters, viz., CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25, named after
the enzyme first discovered for each lineage (Edelstein et aI, 2003; Pagani et aI., 2003;
Bonnet, 2004; Eckert et aI., 2004; Mugnaioli et aI., 2006). Within each cluster there is a
high degree of blaCTX gene sequence identity (>95%), although members of different
subtypes share only 70% to 77% similarity at nucleotide level. The finding ofKLuyvera
ascorbata species-specific p-Iactamases (KluA) which share 98.6 to 100% identity with
CTX-M-2 and CTX-M-5 and analysis of DNA sequences adjacent to the KluA- and
CTX-M-coding genes provide strong evidence of the direct evolution of the CTX-M-2
cluster from the chromosomal enzyme ofK. ascorbata (Baraniak et aI., 2002; Edelstein
et al., 2003) . Likewise, the chromosomal KLUG-1enzyme of Kluyvera georgiana was
found to be the most probable source of the CTX-M-8 that shares 99% identity with
KLUG-1 (Edelstein et aI., 2003; Pagani et aI., 2003). The origin of the other CTX-M
clusters are not so evident yet, although a number of class A chromosomal p-Iactamases,
including KLUC-1 ofKLuyvera cryocrescens, FONA of Serratiajonticola, RAHN-1 of
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Rahnella aquati!is, OXY-1 ofKlebsiella oxytoca and SED-1 of Citrobacter sedlakii
display partial (72.9 to 85.9%) homology with different CTX-M enzymes (Bonnet et a!.,
2000; Edelstein et a!., 2003).
In contrast with TEM- and SHY-type ESBLs, most of the CTX-M enzymes are much
more active against cefotaxime and ceftriaxone than against ceftazidime displaying
significantly higher levels of resistance to cefotaxime compared with ceftazidime
(Baraniak et al., 2002; Ma et aI., 2002; Edelstein et a!., 2003; Woodford et aI., 2004).
However, the classical phenotype of resistance conferred by CTX-M ~-lactamases is not
universal among all CTX-M producers, since many factors, including production of
additional ~-lactamases or mutations altering the substrate specificity of CTX-M enzymes
can mask their presence (Edelstein et a!., 2003). ESBLs belonging to this type, named
cefotaximases (CTX-M), have caused outbreaks of cefotaxime-resistant enterobacteria
mainly in South America, Eastern Europe and Japan (Oliver et a!., 2001).
When first reported in literature, ESBL-producillg organisms were found in nosocomial
isolates from large metropolitan hospitals. Today, ESBLs have been identified world-
wide, not only from major teaching hospitals but also from community hospitals and
nursing homes. The rapid spread ofESBLs has caused significant threats to the therapy
for infections and usage of expanded-spectrum ~-lactams (Yang et a!., 1998).
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1.3.3. AMPC p-LACTAMASES
This pattern of resistance to both cefoxitin and ~-lactamase inhibitors coupled with
reduced susceptibility to third generation cephalosporins is often referred to as the
"AmpC phenotype" (Forward et a/., 2001). The emergence of E. coli strains resistant to
extended-spectrum cephalosprins and cephamycins is a major concern to clinicians
(Clarke et al., 2003). Strains have become resistant by overexpression of chromosomally-
encoded AmpC ~-lactamasesor by acquisition of a transferable ampC gene on a plasmid
or other transferable element. The transferable ampC gene products are commonly called
plasmid-mediated AmpC ~-lactamases (Perez-Perez & Hansoll, 2002; Clarke et a/., 2003)
and the majority is found in nosocomial isolates ofE. coli and K. pneumoniae (Perez-
Perez & Hanson, 2002). Plasmid-mediated ampC genes are derived from the
chromosomal ampC genes of several members of the family Enterobacteriaceae,
including Enterobacter cloacae, Citrohacterfreundii, Morganella morganii and Hafnia
alvei (Forward et al., 2001; Perez-Perez & Hanson, 2002). In E coli, resistance provided
by class C ~-lactamases can be plasmid-mediated or due to overexpression of the
chromosomal ampC gene (Tracz et a/., 2005) Chromosomally encoded and plasmid-
encoded AmpC ~-lactamases,with the exception of ACC-1, confer resistance to many ~­
lactams including cephamycins and ~-Iactam ~-Iactamase inhibitors (Lee et al., 2004).
1.3.3.1. CHROMOSOMAL AMPC P-LACTAMASES
The AmpC cephalosporinase gene in E. coli is normally located on the chromosome and
is weakly expressed because of a weak promoter and a weak transcriptional attenuator.
Wild-type strains produce a basal level of this enzyme which does not result in ampicillin
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and cephalosporin resistance. This enzyme can be hyper-produced due to genetic
variation. Although AmpC ~-Iactamases are responsible for antibiograms similar to
ESBLs, they are poorly inhibited by ~-Iactam ~-Iactamase inhibitor combination (Siu et
al., 2003). The production of the AmpC ~-Iactamase in E. coli is not inducible, as are
most class C cephalosporinases, but is constitutive because of the absence of the ampR
regulator gene (Caroff et aI., 2000; Corvec et ai, 2002) and the level of transcription of
the ampC gene thus depends mostly on the strength of the ampC promoter (Corvec et al.,
2002).
Strains carrying the wild-type gene produce a low basal amount of AmpC and are
susceptible to ampicillin (Mulvey et al., 2005). Mutations in the promoter region of
ampC have been described as the mechanism for AmpC hyper-production (Tracz et aI.,
2005). Numerous mutations have been described in the ampC promoter of clinical strains
hyperproducing a chromosomal cephalosporinase. The most frequently described E. coli
ampC 'strong' promoter harbours mutations at positions -88, -82, -42, -18, -1 and +58
(Caroff et aI., 2000). E. coli promoters harbour two hexamers of conserved sequences,
the -35 region and the -10 one, called the Pribnow box, which play an important role in
the level of gene transcription. The -35 consensus sequence TTGACA and the -10
consensus sequence TATAAT have been defined. The closer to the consensus the
sequences are, the stronger the promoter. The interbox distance also plays an important
role in the transcription rate. Ideally it is ] 7bp long (Corvec et al., 2002). Attenuator
mutations are thought to destabilize the hairpin structure allo\\-ing for greater read
through (Tracz et aI., 2005).
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Although poorly expressed in E. coli, these enzymes are impoltant to recognize since
they provide an even broader spectrum of resistance (Alvarez et aI., 2004).
1.3.3.2. PLASMID-MEDIATED AMPC P-LACTAMASES
Plasmid-mediated AmpC p-lactamases, first reported in 1988 (Mulvey et al., 2005), have
arisen through the transfer of chromosomal genes for the inducible AmpC p-lactamase
onto plasmids (Thomson, 2001; Mulvey et ai., 2005). These plasmid-mediated genes are
of special interest because their mobility allows them to emerge in one genus or species
and spread to different organisms (Mulvey et aI., 2005).This transfer has resulted in
plasmid-mediated AmpC p-lactamases in isolates ofE. coli, K. pneumoniae, Salmonella
spp, C../reundii, E. aerogenes and P. mirahilis. Most of the plasmid-mediated AmpC P-
lactamases have similar substrate profiles to the parent enzymes from which they appear
to be derived (Thomson, 2001). Plasmid-mediated AmpC p-lactamases have been derived
from chromosomal AmpC genes ofC.!reundii (CMY-2A, LAT-l and BIL-l) (Odeh et
al., 2002; Batchelor et aI., 2005), E. cloacae (MlR-I) and P. aeruginosa (MOX-l and
FOX-I) (Odeh et aI., 2002).
1.4. MOTIVATION FOR STUDY
Various classes of p-lactamases have been reported throughout the world in E. coli
including TEM- (Kaye et al., 2004), SHV- (Rasheed et al., 1997), CTX-M- (Woodford et
al., 2004) and plasmid-mediated AmpC-type p-Iactamases (Philippon et al., 1989;
Gazouli et al., 1996; BOll et aI., 2000; Girlich et al., 2000; Van et al., 2006). Resistance
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to the ~-lactam antibiotics amongst E. coli clinical isolates is an increasing problem
world-wide. The development of ~-lactamasemediated resistance in E. coli has several
clinical implications (Clarke et al., 2003).
This study investigated ~-lactamase mediated resistance in E. coli isolated in 16
demographically representative public hospitals at three levels of health care in
KwaZulu-Natal. A total of 1270 bacterial isolates were collected; of which 300 (23.6%)
were E. coli isolates. One hundred and seventy-nine of these isolates were resistant to one
of the three antibiotic-inhibitor combinations used in this study; 38 isolates were selected
on the basis of their resistance profiles to the three antibiotic/inhibitor combinations, viz.,
amoxicillin/ clavulanate, ampicillin/ sulbactam and piperacillin/ tazobactam.
1.5. AIM
To phenotypically and genotypically characterize ~-lactamase mediated resistance in E.
coli isolated in state hospitals in KwaZulu-Natal.
1.6. OBJECTIVES
1. To identify the bacterial isolates using the API20E identification system.
2. To determine antibiotic susceptibility using Kirby Bauer disc diffusion method
following CLSI guidelines against a range of ~-Iactam antibiotics.
3. To detect the presence ofESBLs using appropriate ESBL E-test strips
4. To detect the presence of ~-lactamasesby iso-electric focusing (IEF).
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5. To detect the presence of plasmids encoding resistance using the alkaline lysis
method.
6. To detect the presence of~-Iactamase genes such as TEM-, SHV-, CTX-M- and
plasmid-mediated AmpC ~-Iactamases and changes in chromosomal AmpC ofE.
coli by PCR using appropriate primers.
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Two Escherichia coli isolates which were isolated from the urine of patients in state hospitals in
KwaZulu-Natal, South Africa were investigated to determine the sequence of the TEM J3-lactamases
responsible for their resistance to J3-lactamase inhibitors. The isolates were subjected to MIC
determinations, iso-electric focusing analysis, plasmid analysis, polymerase chain reaction (PCR) for
the detection of J3-lactamase genes and sequencing of the blarEM. Analysis of the nucleotide sequences
revealed the presence of two novel TEM J3-lactamases, TEM-14S and TEM-146 which had the R244H
mutation. Mutations at position 244 have been previously reported in other inhibitor-resistant TEMs
(IRTs).
Key words: Escherichia co!i, plasmid-mediated, TEM ~-Iactamase.
INTRODUCTION
~-Iactam antibiotics are the most frequently prescribed
antimicrobial agents in clinical practice (Canica et aI.,
1998; Pitout et aI., 2005). In response, bacteria have
acquired resistance to these antibiotics. In parallel with
molecular modifications introduced to overcome this
resistance, bacteria have modified their resistance
mechanisms. The most significant mechanism of
resistance to the ~-Iactam antimicrobial agents is the
production of ~-Iactamase enzymes (Blasquez et aI.,
2000; Morris et aI., 2003). In members of the family
Enterobacteriaceae, the most prevalent mechanism of
resistance to broad-spectrum ~-Iactams is detoxification
of the drugs by plasmid-mediated enzymes that are
variants of TEM and SHV penicillinases. The TEM-
derived extended-spectrum ~-Iactamases (ESBLs) or
inhibitor-resistant ~-Iactamases differ from the parental
TEM-1 and TEM-2 penicillinases by various combinations
of amino acid substitutions (Goussard and Courvalin.
1999).
'Corresponding author. E-mail MOCKTARC@ukzn.ac.za. Tel:
+2731 2607358. Fax: +2731 2607792.
Amoxicillin/clavulanate is a ~-Iactam-~-Iactamase inhi-
bitor combination that has antimicrobial activity against a
wide variety of organisms. Escherichia co!i, one of the
most common pathogens, is usually susceptible to amo-
xicillin/clavulanate (Kaye et aI., 2004). However, resis-
tance has begun to emerge. The use of ~-Iactam-~-Iacta­
mase inhibitor combinations has selected mutant deriva-
tives of the TEM and SHV families of class A ~-Iactama­
ses that have become relatively resistant to inactivation
by ~-Iactamase inactivators and thereby confer resistan-
ce to these combinations (Vakulenko et aI., 1998). Resis-
tance to amoxicillin/clavulanate appeared first in E. co!i
isolates and then in other species of enterobacteria
(Speldooren et aI., 1998). Resistance to the combination
of amoxicillin and clavulanate in strains of E. coli may be
due to a numbers of factors, four of which are enzymatic,
viz., hyper-production of class C chromosomal ~-Iactama­
se, hyper-production of plasmid-mediated TEM-1 or
TEM-2, production of inhibitor-resistant TEM (IRT) and
the production of a relatively inhibitor-resistant OXA-type
~-Iactamase (Sirot et aI., 1994; Speldooren et aI., 1998).
In this study we report the presence of two novel TEM
~-Iactamases; TEM-145 and TEM-146 which were found
in two E. co!i clinical isolates.
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Table 1. Primers used in PCR studies.
Primer Sequence PUll)ose of primer Reference
TEM1(F) 5'-ATGAGTATTCAACATTTCCGTG-3' Amp Essack et aI., 2001
TEM2(R) 5'-TTACCAATGCTTAATCAGTGAG-3' Amp/Seq Essack et aI., 2001
TEM3(R) 5'-TTCTGTGACTGGTGAGTACT-3' Seq Essack et aI., 2001
TEM4(R) 5'-GAGTAAGTAGTTCGCCAGTT-3' Seq Essack et aI., 2001
TEM5(F) 5'-CTGCAGCAATGGCAACAAC-3' Amp/SeQ DesiQned for this study
F, forward primer; R, reverse primer; Amp, amplification; Seq, sequencing.
MATERIAL AND METHODS
Bacterial Strains
E. coli NWE11 and E. coli PMM40 were isolated from the urine samples
of patients in hospitals in Kwalulu-Natal, South Africa in 2000. The
identity of the strains as E. coli was confirmed using the API20E
identification system (bioMerieux sa, Lyon, France). E. coli ATCC 25922
and E. coli NCTC 50192 served as the control for determination of
minimum inhibitory concentrations (MIC) and plasmid size analysis
respectively. E. coli CF204 was used as a TEM-3 positive control.
Antibiotic susceptibility testing
Susceptibility testing was undertaken using the Kirby Bauer disc diffu-
sion method according to CLSI (formerly NCCLS) gUidelines. The
following antibiotics were used: ampicillin, ampicillinlsulbactam, amoxi-
cillinlclavulanate, ticarcillin, piperacillin, piperacillinltazobactam, cepha-
lotin, cefuroxime-parenteral, cefoxitin, ceftriaxone, cefotaxime, ceftazi-
dime, cefepime, meropenem and aztreonam (Mast Diagnostics, Mer-
seyside, UK). MIC values were extrapolated by the BIOMIC automated
reading system and software package (Giles Scientific, New York).
Plasmid size analysis
Plasmid DNA was extracted from overnight cultures in Nutrient Broth
(Biolab, Johannesburg, South Africa) using the alkaline lysis method
(Kado and Liu, 1981). Plasmid sizes were calculated using computer
software (Syngene-Gene Genius, Bio Imaging Systems, Syngene).
I3-Lactamase analysis
The 13-lactamases were extracted from pure overnight cultures in
Nutrient Broth (Biolab, Johannesburg, South Africa) by the freeze-thaw
method (Livermore and Williams, 1996). Analytical isoelectric focusing
(IEF) was performed in ampholine polyacrylamide gels (pH 3.5- 9.5;
Amersham Biosciences, Uppsala, Sweden). 13-lactamase bands were
detected with nitrocefin solution ( 0.05% (w/v); Oxoid, Hampshire,
England). An isoelectric point marker pi calibration kit (4.7 to 10.6; BDH,
England) was the standard used.
peR detection of b1arEMgenes
A suspension of colonies from an overnight culture on Nutrient Agar
(Blolab, Johannesburg, South Africa) was made in purified water (50 ~I).
Bacterial DNA was prepared by heating this suspension at 95°C for 5
min. PCR amplifications were then performed in a Gene Amp PCR
System (Applied Biosystems, Claifornia, USA). The primers (Inqaba
Biotechnology, Pretoria, South Africa) used are described in Table 1.
The amplification of blarEM genes was carried out as described
previously (Essack et ai., 2001). PCR products (5 ~I) were analyzed by
gel electrop.horesis. Gels were stained with ethidium bromide and
photographed using UV illumination. PCR products were purified and
sequenced (Spectrumedix SCE2410 genetic analysis system,
Spectrumedix, Pennsylvania, USA).
Nucleotide sequence accession number
The sequences obtained were analyzed using the BLAST 2.0 software
available on the website of the National Centre for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/Blast; last accessed June
2006). The nucleotide and amino acid sequences of TEM-145 and
TEM-146 were deposited in GenBank and assigned the accession num-
bers 00105528 and 00105529, respectively.
RESULTS AND DISCUSSION
The MIC results are shown in Table 2. Both isolates were
resistant to amoxicillin/c1avulanate and ampicillin/sulbac-
tam. E. coli PMM40 was resistant to piperacillin/tazobac-
tam whilst E. coli NWE11 displayed intermediate resis-
tance to piperacillin/tazobactam. Plasmids of 129.2 kb
and 112.2 kb and 112.1 kb were detected in E. coli
NWE11 and E. coli PMM40, respectively. IEF analysis
revealed two ~-lactamase bands for each of the isolates.
~-lactamases with iso-electric points of 6.0 and 7.8 and
6.6 and 8.6 were detected for E. coli NWE11 and E. coli
PMM40, respectively. PCR amplification revealed that
both isolates harboured blaTEM genes and also the E. coli
chromosomal AmpC gene (results not shown).
Sequencing data identified the TEM genes as follows: E.
coli NWE11 carried TEM-1 and TEM-146 (novel) and E.
coli PMM40 carried TEM-1 and TEM-145 (novel). All
isolates were also tested for the presence of SHV-, CTX-
and plasmid-mediated CMY-genes (results not shown)
but these were not found. The ~-Iactamases with pi
values of 6.0 and 6.6 could be identified as transcripts of
TEM ~-Iactamase genes and those with pi values of 7.8
and 8.6 as transcripts of the E. coli chromosomal AmpC
genes. The TEM-~-Iactamase enzymes showed the
following changes compared to TEM-1 : TEM-145 had two
changes; L221 M and R244H, while TEM-146 had three
changes; T114P. M1821 and R244H.
Resistance to the ~-Iactam-~-Iactamase inhibitor com-
binations and ESBLs in E. coli is an emerging problem
(Kaye et aI., 2004). The emergence of IRT-producing
strains might be related to the frequent use of inhibitor-
containing formulations in hospitals and in general
practice (Chaibi et aI., 1999).
The R244H mutation, found in TEM-145 and TEM-146
Table 2. MICs (~g/ml) of the E. coli isolates investigated in
this study.















Abbreviations: AMP, ampicillin; SAM, ampicillin! sulbactam; AMC,
amoxicillin/c1avulanate; PIP, piperacillin; TZP, piperacillinltazobac-
tam; CEF, cephalotin; CXM, cefuroxime-parenteral; FOX,
cefoxitin; CRO, ceftriaxone; GTX, cefotaxime; GAZ, ceftazidime;
FEP, cefepime; MEM, meropenem; ATM, aztreonam; (I) denotes
intermediate resistance, boldface denotes resistance.
~-Iactamases, has been found in only one other TEM ~­
lactamase, viz., TEM-57 (IRT-15). Other reported
mutations of Arg-244 are substitutions with serine, cystei-
ne, glycine and leucine (www.lahey.org/studies/tem-
table.asp, last accessed June 2006). In the TEM-1
enzyme, Arg-244 is located on strand ~4' Its side chain
overlaps strand ~3 and thereby takes part in interactions
with the substrate in the active site (Bret et al., 1997).
When Arg-244 is replaced by an amino acid with a short
side chain such as cysteine, serine or histidine, the enz-
yme-substrate interaction is modified and affinity for the
substrate decreases. Moreover, the shorter side chains of
these residues would be unable to activate the water
molecule involved in the inactivation process of clavu-
lanate (Bret et al., 1997; Chaibi et al., 1999). Site-specific
mutations induced at the active site of TEM ~-Iactamase
has confirmed that replacement of arginine by serine,
cysteine or threonine leads to clavulanic acid resistance
(Bret et al., 1997). Sulbactam and tazobactam are
thought to use a different mechanism and are not
dependent on the structurally conserved water molecule
(Chaibi et al., 1999).
The M1821 found in TEM-146 ~-Iactamase has not
been reported before. The other substitution reported at
this position is the substitution of a threonine for the
methionine. The M182T mutation has been reported for
TEM-20, TEM-32 (IRT-3), TEM-43, TEM-52, TEM-63/64,
TEM-72, TEM-87, TEM-88, TEM92-94, TEM-106, TEM-
107, TEM-113, TEM-124, TEM-126, TEM-131, TEM-135
and TEM-149 (www.lahey.org/studies/temtable.asp, last
assessed June 2006). Residue182 which is located just
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before the a-8 helix is far from the active site (Chaibi et
al., 1999) and the M182T mutation has been found in
several natural ESBL mutant enzymes. It has been
shown by thermodynamic and enzymatic studies that this
substitution does not affect ~-Iactamase activity but acts
as a global stabilizer. The M182T substitution restores
the stability lost by substitutions near the active site and,
hence, is a rescue substitution for TEM ESBL-type
mutants (Delmas et al., 2005). The T114P mutation is the
first report of a mutation at this position.
IEF analysis showed that the E. coli isolates each
produced two enzyme bands but each of the isolates
possessed three enzymes, i.e., TEM-1, the E. coli
chromosomal AmpC and either TEM-145 or TEM-146.
Also, the reported pi values for most IRTs has been 5.2
to 5.4 (Chaibi et al., 1999). A possible reason for the
presence of only two IEF bands instead of three could be
the minimal expression of TEM-145ffEM-146, hence two
IEF bands. The pi values of 6.0 and 6.6 is not typical of
an IRT. This could possibly be attributed to minimal
expression of TEM-145 and TEM-146.
Conclusion
The resistance of the isolates to the inhibitor combina-
tions could be attributed to the presence of TEM-145 and
TEM-146 ~-Iactamases which each had a mutation at
position 244.
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Abstract
In this study, we report the presence of a novel plasmid-mediated AmpC-type a-Iactamase that was isolated from 3 clinical
Escherichia coli isolates at a tertiary teaching hospital in Durban, South Africa. The nucleotide sequence of the genes encoding
this novel r,-Iactamase was found to be >94% identical to the nucleotide sequences of the plasmid-mediated AmpC-type r:.-
lactamases originating from Citrohacter freundii. This enzyme differed from CMY-2 by 3 amino acid substitutions and was
designated CMY-20.
t9 2008 Elsevier Inc. All rights reserved.
Keywords: CMY-20; £,cherichia coli; Plasmid-mediated I~-Iactamase
1. Introduction
The emergence of resistance to the cephalosporins,
cephamycins, and f;-Iactamase inhibitors among members
of the family Enterobacteriaceae and, in particular,
Escherichia coli clinical isolates is a cause for concern.
This broad spectrum of resistance to these antibiotics is a
common feature of the AmpC class of enzymes (Bush
et aI., 1995). Plasmid-mediated cephalosporinases confer-
ring resistance to oxyimino-cephalosporins and cepha-
mycins as well as to 13-1actarnase inhibitors have been
described since 1989. Many of them have amino acid
sequences close to those of chromosomal-encoded and
inducible AmpC enzymes of the family Enterobacteriaceae
(Doi et aI., 2002).
These plasmid-mediated cephalosporinases have been
classified into clusters corresponding to a typical geographic
location such as the North American cluster (MlR-I and
ACT-J), CentJ'al and South American cluster (FOX-J and
FOX-2), Asian cluster (CMY-l and MOX-J), and Mediter-
ranean Middle East cluster (CMY-2, CMY-2b, LAT-I and
" Corresponding author. Tel.: +27-31-260-7358; fax: +27-31-260-7792.
E-mail addre.s:mocktarc@ukm.ac.za (C. Mocktar).
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LAT-2) (Verdet et aI., 1998). The most widespread plasrnid-
mediated AmpC 13-lactamases are those derived from the
chromosomal cephalosporinases of Citrobacter freundii
(Miriagou et al., 2004).
In this study, we report the presence ofa novel CMY-type
AmpC ~}-lactamase, CMY-20, isolated from 3 E. coli isolates
out of a total of 330 from a study investigating 13-lactam-
mediated resistance to commonly used antibiotics in public
sector hospitals in South Africa.
2. Methods and materials
2.1. Bacterial strains
E. coli KEH1 and E. coli KEH42 were isolated from
peritoneal fluid and E. coli KEH32 from a pus swab from
3 different patients in a tertiary teaching hospital in
Durban, South Africa, in 2000. Identification of the E. coli
isolates were confirmed using the API20E identification
system (bioMerieux, Lyon, France). E. coli ATCC 25922
was used as the quality control for susceptibility testing,
and E. coli NCTC 509 J2 was the reference strain used to
determine plasmid size. E. coli J62-1 was used as the
recipient in the conjugation experiments (Livermore and
Corkill, J992).
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2.2. Antibiotic susceptibility testing
Susceptibility testing was undertaken using the disc
diffusion test according to the NCCLS (2003) guidelines.
MIC values were extrapolated by the BIOMIC, an automated
reading system and software (Giles Scientific, New York,
NY), using the following antibiotics: ampicillin, piperacillin,
ticarcillin, carbenicillin, amoxicil1inlclavulanate, ampicillin!
sulbactam, piperacillinltazobactam, cefalotin, cefuroxime-
parenteral, cefepime, cefoxitin, cefotaxime, ceftriaxone,
ceftazidime, meropenem, aztreonam, amikacin, trimetho-
prim! sulfamethoxazole, and chloramphenicol (Mast Diag-
nostics, Merseyside, UK).
2.3. Plasmid size analysis and resistance transfer
Plasmid DNA was extracted from the E. coli isolates
using the alkaline lysis method (Kado and Liu, 19R I).
Plasmid sizes were calculated using computer software
(Syngene-Gene Genius, Bio Imaging Systems, Syngene,
Cambridge, UK).
Mating experiments were performed by mixing equal
quantities ofovernight nutrient broth (BioIab, Johannesburg,
South Africa) cultures of the clinical isolate as donor and E.
coli J62-1 as the recipient, and incubating the mixture for 6 h
at 37°C. The cefoxitin-resistant E. coli J62-1 transconju-
gants were selected on MacConkey agar (Biolab) supple-
mented with nalidixic acid (50 f..l.g!mL) and cefoxitin (10 fig!
n1.L). MlCs (antibiotics listed in Table 2) of the transconju-
gant were determined, and the transconjugant was also
subjected to polymerase chain reaction (PCR) for the
detection of the blactvfY gene.
2.4. f3-Lactamase analysis
The f3-lactamases of the E. coli clinical isolates were
extracted from a nutrient broth (Biolab) culture by the
freeze-thaw method (Livermore and Williams, 1996). Ana-
lytical isoelectric focusing (lEF) was performed in ampholine
polyacrylamide gels (pH 3.5-9.5; Amersham Biosciences
Uppsala, Sweden). ~"'-Lactamase bands were detected with
rutrocefin (Oxoid, Basingstoke, UK). An isoelectric point
Table I
Primers used in PCR studies
marker pI calibration kit (4.7-10.6; BDH, Poole, UK) was
lISed as the standard.
2.5. peR detection and molecular characterization
of f3-lactamases
Bacterial DNA was prepared by suspending few freshly
grown colonies from an overnight Nutrient Agar (Biolab)
culture of E. coli in 50 flL of purified water and heating the
cells at 95°C for 5 min. PCR amplifications were then
performed in a Gene Amp PCR System (Applied Biosys-
terns, Foster City, CA). PCR conditions for the amplification
of blaTEM genes were carried out as described previously
(Essack et aI., 2001). The amplification mixture for the
detection of the blac"1>.1Y gene was made up to 50 I.iL and
contained 25 fiL AmpliTaq Gold PCR Master Mix (Applied
Biosystems), purified water, 10 pmol of each primer (Inqaba
Biotechnology, Pretoria, South Africa; refer to Table 1), and
2 flL of the template DNA. PCR conditions were as follows:
an initial denaturation for 3 min at 94°C, 30 cycles of30 sat
94°C, 30 s at 55°C, 1 min at 72 QC, and a final extension
step of7 min at 72 QC. PCR products (5 flL) were analyzed
by gel electrophoresis. Gels were stained with ethidium
bromide and photographed using UV illumination. PCR
products were purified and sequenced (Spectrumedix
SCE2410 genetic analysis system; Spectrumedix, State
College, PA). The isolates were also tested for the presence
of blasHv (Essack et aI., 2000), blacTX (Edelstein et aI.,
2003), blaMox (Perez-Perez and Hanson, 2002), blaFOx
(Perez-Perez and Hanson, 2002), blaDl-lA. (Perez-Perez and
Hanson, 2002), blaAcc (Perez-Perez and Hanson, 2002), and
hlaACT (Perez-Perez and Hanson, 2002) genes by PCR. In
addition, the promoter and attenuator regions of the
chromosomal AmpC of E. coli were also investigated to
determine whether there were any mutations in these regions.
2.6. Nucleotide sequence accession number
The sequences obtained were analyzed using the BLAST
2.0 software available on the Web site of the National Centre
for Biotechnology Information (http://www.ncbi.nlm.nih.
Primer Sequence ... ... . ....... ........._.__.. ....__.. ... ~_urpos~ o~.pnmer Reference
TEM l(F) 5'-ATGAGTATICAACATTTCCGTG-3' Amp - ...- .........-.....- ..--------------------.-.--
TEM 2(R) 5'-TIACCAATGCTIAATCAGTGAG-3' Essack etal. (2001)
TEM 3(R) 5'·TTCTGTGACTGGTGAGTACT·3 , ~:P/Seq Essack et al. (2001)
TEM 4(R) 5'-GAGTAAGTAGTICGCCAGTT-3' Seq Essack et a1. (2001)
TEM 5(F) 5'.CTGCAGCAATGGCAACAAC-3' Essack et al. (2001)
CMY-F 5'-GACAGCCTCTTTCTCCACA.Y Amp/Seq Desiglled for this study
CMY-R 5'-TGGAACGAAGGCTACGTA-3' ~~~~~:~ Zhao et at. (2001)
CMY-FI 5'-GAAAAAATCGTIATGCTGC-3 Zhao et a1. (2001)
C
Amp/Seq D' d r thi
MY-RI 5'-CCGTATAGGTGGCTAAGTGC.3' Amp/Seq eSlglle 101' s study
CMY-F2 5'-GTGAAATCCAGCGTIATIGA.Y Designed for this studyAmp/Seq D' d r th'
CMY-R2 5'-CTITICAAGAATGCGCCAGG.3' Amp/Seq eSlglle ,or IS studyDesigned for this study
F forward primer; R reverse primer; Amp arnplificatioll; Seq ~equencing.
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4. Discussion
This study also reported a mutation in the same position but
with a different anuno acid (S309N). This is the 1st report of
the R125S and R146T mutations. All the isolates were
negative for the presence of the other fl,-lactamases tested.
The isolates did not display any changes in the promoter
and attenuator regions of the chromosomal AmpC. The
E. coli J62-1 transconjugants all showed similar resistance
profiles as their donors. PCR showed the presence of a
CMY-type [>'-lactamase.
Strains with plasmid-mediated AmpC enzymes are
generally resistant to arninopenicillins, carboxypenicillins,
and ureidopenicillins. The enzymes also provide resistance
to cephalosporins in the oxyimino and the 7-o:-methoxy
groups. In addition, these enzymes are also active against
aztreonam, although some strains are susceptible to this
antibiotic. With regard to the 13-lactamase inhibitors, E. coli
derivatives with plasmid-mediated AmpC enzymes are
generally resistant to inhibitor combinations, with the
possible exception of tazobactam (Philippon et aI., 2002).
In a previous study (Verdet et aI., 1998), Proteus mirabilis
harboring CMY-4 was susceptible ceftazidime and piper-
acillinltazobactam and displayed intermediate resistance to
cefoxitin, whereas in another study (Decre et aI., 2002), the
isolates harboring CMY-4, CMY-12, and CMY-2 were
susceptible to piperacillinltazobactam and, with the excep-
tion of the Klebsiella pneumoniae isolate harboring CMY-2,
were susceptible to aztreonam. Furthermore, plasmids
encoding AmpC enzymes often carry mUltiple resistance
genes, conferring resistance to aminoglycosides, chloram-
phenicol, sulfonarnides, tetracycline, trimethoprim, or mer-
curic ion (Stapleton et aI., 1999). In this study, the 3 clinical
E. coli isolates investigated were also found to be multi-
resistant, conferring resistance to amikacin, trimethoprim-
sulfamethoxazole, chloramphenicol, and gentamicin, in
addition to the fS-lactam antibiotics described above.
The amino acid sequence of CMY-20 showed that this
enzyme had the ~-lactamase active site SVSK at residues 64
to 67, the conserved KTG triad at residues 315 to 317, and
the typical class C YXN motif (Decre et aI., 2002; Philippon
et a\., 2002), thus, indicating that the enzyme was an AmpC-
type 13-lactamase. Analysis of the sequence of CMY-20
using Blast 2.0 revealed a high degree of homology with
other plasmid-encoded AmpC [>'-lactamases such as BIL-1,
LAT-1, CMY-2, and LAT-2, which are closely related
to the chromosomal ampC gene of C. freundii, suggest-
ing mobilization of the chromosomal ampC gene from
C. Jreundii onto plasmids (Bauernfeind et aI., 1996;
Koeck et aI., 1997).
The appearance of plasmid-borne AmpC [>'-lactamases
should be a cause for concern. Genes for the AmpC enzymes
have been located on plasmids of varying sizes (Horii et aI.,
























































































MIC (llglmL) profiles of the E. coli clinical isolates and the transconjugant
of E. coli KEH32
The MIC results for the E. coli clinical isolates
investigated in this study are shown in Table 2. These
isolates were resistant to all the cephalosporins tested as well
as the I~-lactamase inhibitor combinations, but susceptibility
to cefepime and meropenem was retained. Each of the 3 E.
coli isolates harbored a single 148.5-kb plasmid. lEF
analysis revealed the presence of ~}-lactamases with pIs of
6.0,5.9, and 6.6 inE. coli KEH1,E. coli KEH32, andE. coli
KEH42, respectively, and sequencing data showed that these
isolates harbored TEM-I. 1EF also revealed the presence of
f3-lactamases with pI values of7 .8, 7.7, and 8.0, respectively.
These values are consistent with the production of AmpC-
type r5-lactamases. Sequencing data showed that the 3
isolates harbored a novel plasmid-mediated AmpC-type
!>'-lactamase. This novel cephalosporinase, assigned CMY-20,
is a member of the C./reundii group and differs from CMY-2
by the following substitutions, viz., R125S, R146T, and




















oov/Blast· last accessed June 2006). The nucleotide and
:mino acid sequences of the CMY-type 13-lactamases of the
isolates were deposited in GenBank and assigned the
following accession numbers: E. coli KEHl AY960293, E.
coli KEH32 AY936494, and E. coli KEH42 AY940316.
AMP =ampicillin; PIP =piperacillin; TIC = ticarcillin; CAR =carbenicillin;
AMC = amoxicillin!c1avulanate; SAM = ampicillin! sulbactam; TZP =
piperacillin! tazobactam; CEF = cefalotin; CXM = cefuroxime-parel1teral;
FEP = cefepime; FOX = cefoxitin; CTX = cefotaxime; CRO =
ceftriaxone; CAZ = cefulzidime; MEM = meropel1em; ATM = aztreol1am;
AMK = anlikacin; TMPISXT = trimethoprim sulfamethoxazole; ('HL =
chloramphenicol.
--------------------------------------------------------
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Plasmid-mediated AmpC enzymes can confer resistance
to all (?>-lactams other than 4th-generation cephalosporins
and carbapenems and hence pose a major therapeutic
challenge. It is thus imperative to institute surveillance
systems to monitor the further dissemination of these
emerging cephamycin-resistant Gram-negative bacteria.
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all are self-transmissible, are transferable by transfOlmarion
(Stapleton et al., 1999) or mobilization onto integrons and
gene cassettes (Gazouli et al., 1997).
Plasmid-mediated class C I~-Iactarnases have been found
worldwide, most frequently in K. pneumoniae and, to a
lesser extent, in E. coli, P mirabilis, and the salmonellae.
They have been reported in Africa (Algeria and Tunisia),
Asia, Europe, the Middle East, North America, and South
and Central America. CMY-2 is the most prevalent of the
plasmid-mediated AmpC enzymes and the most widely
distributed geographically (Decre et al., 2002; Philippon
et al., 2002). Although the plasmid-mediated AmpC-type r~­
lactamases have been found throughout the world, their
occurrence on the African continent is relatively rare, and
there have been few documented reports (Philippon et al.,
2002). The only report ofCMY-type enzymes in Africa, thus
far, has been the characterization of a plasmid-mediated
CMY-2 [)-lactamase from an Algerian isolate of Salmonella
sen/tenberg (Koeck et aI., 1997), and the other report was of
a CMY-4 plasmid-mediated [)-Iactarnase from a Tunisian P
mirabilis clinical isolate (Verdet et al., 1998). Thus far, there
have been no documented reports of plasmid-mediated
CMY-2-type ~,-lactamases in E. coli in Southern Africa, and
to the best of our knowledge, this is the 1st report of a
Southern African E. coli clinical isolate harboring a CMY-2
lype rs-Iactamase.
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The ampC promoter and attenuator regions of an Escherichia coli clinical isolate from a public hospital
in KwaZulu-Natal was investigated to detect the presence of mutations in these regions. The isolate was
subjected to MIC determinations, IEF analysis, PCR for the presence of (3-lactamases and sequencing of
the ampC gene. Analysis of the ampC promoter and attenuator regions of the isolate showed that the
isolate had mutations in the promoter region and this included insertions of nucleotides in the spacer
region between the -10 and -35 Pribnow boxes. The insertion of an extra nucleotide in the spacer region
between the -10 and -35 boxes affects the resistance of bacteria to (3-lactam antibiotics.
Key words: Escherichia coli, promoter, pribnow box.
INTRODUCTION
All strains of Escherichia coli possess a gene that
encodes an AmpC 13-lactamase (Clark et aI., 2003). The
AmpC gene in E. coli is normally located on the chromo-
some and is weakly expressed because of a weak
promoter and a weak transcriptional attenuator (Siu et aI.,
2003; Mulvey et al., 2005). Most E. coli strains do not
produce clinically relevant levels of the chromosomally
encoded AmpC 13-lactamase (Martinez-Martinez et aI.,
2000). Wild-type strains produce a basal level of this
enzyme which does not result in ampicillin and
cephalosporin resistance (Siu et aI., 2003; Mulvey et aI.,
2005). Gene amplification or mutations at either the
promoter and/or attenuator regions of the structural 13-
lactamase gene can result in AmpC hyper-production
(Martinez-Martinez et al., 2000). Such hyper-production
of AmpC 13-lactamase contributes to resistance to ampi-
cillin, extended-spectrum cephalosporins and 13-lactam-l3-
lactamase inhibitor combinations (Martinez-Martinez et
*Corresponding author: E-mail: mocktarc@ukzn.ac.za. Tel: +27
31 2607358; Fax: +27 31 2607792
aI., 2000; Siu et aI., 2003). AmpC 13- lactamases display
similar MIC values to extended-spectrum 13-lactama-
ses (ESBLs). However, in contrast to ESBLs, AmpC 13-
lactamases are poorly inhibited by 13-lactam-I3-lactamase
inhibitor combinations (Siu et al., 2003).
Unlike other members of the family Enterobacte-
riaceae, in E. coli, ampC is not inducible since there is no
ampR regulatory gene (Caroff et al., 2000) and
consequently, in E. coli the level of transcription of the
ampC gene depends mostly on the strength of the ampC
promoter. E. coli harbours two hexamers of conserved
sequences, the -35 region and the -10 one, called the
Pribnow box, which play an important role in gene
transcription. The -35 consensus sequence TTGACA and
the -10 consensus sequence TATAAT have been des-
cribed (Corvec et al., 2002). Genetically, promoter
changes, an oplimized distance (17 bp) in the Pribnow
box (-35 and -10) and the presence of more than one
copy of ampC, have been described as crucial factors for
ampC hyper-production (Nelson and Gay Elisha, 1999;
Siu et al., 2003). Mutations in the promoter region of
ampC have been described as a mechanism for AmpC
hyper-production. The mutations are thought to generate
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Table 1. Primers used in PCR studies.
F, forward primer; R, reverse primer; Amp, amplification; Seq, sequencing.
Primer Seauence Purpose of primer Reference
TEM 1(F) 5'-ATGAGTATICAACATITCCGTG-3' Amp Essack et aI., 2001
TEM 2(R) 5'-TIACCAATGCTIAATCAGTGAG-3' Amp/Seq Essack et aI., 2001
TEM 3(R) 5'-TICTGTGACTGGTGAGTACT-3' Seq Essack et al., 2001
TEM 4(R) 5'-GAGTAAGTAGTICGCCAGTT-3' Seq Essack et al., 2001
TEM 5(F) 5'-CTGCAGCAATGGCAACAAC-3' Amp/Seq Designed for this study
COLA 5'-ACGACGCTCGCGCCTIA-3' Amp/Seq Bret et aI., 1998
COLB 5'-AAGAATCT GCCAGGCGGC-3' Amp/Seq Bret et aI., 1998
AmpC R1 5'-GTITGCTGCGTGACGGGCTG -3' Amp/Seq Designed for this study
AmpC F1 5'-ACCACGCGAT GCACGATCTG-3' Amp/Seq Designed for this study
AmpC R2 5'- GATGACA GCAAGGAAAAGCGGAG-3' Amp/Seq Designed for this study
AmpC F2 5'-GCCGGTAAATCCTGACACCATC-3' Amp/Seq Designed for this study
CTX-MF 5'-TTIGCGATGTGCAGTACCAGTAA-3' Amp/Seq Edelstein et aI., 2003
CTX-MR 5'-CGATATCGTTGGTGGTGCCATA-3' Amp/Sea Edelstein et al., 2003
promoters that more closely resemble the E. coli con-
sensus, which leads to over-expression of the normally
low level constitutively expressed ampC (Mulvey et al.,
2005; Tracz et al., 2005). The most frequently described
E. coli ampC 'strong' promoter harbours mutations at
positions -88, -82, -42, -18, -1 and +58 (Caroff et al.,
2000). Attenuator mutations are thought to destabilise the
hairpin structure allowing greater read-through (Mulvey et
aI., 2005; Tracz et al., 2005).ln this study we examined
the DNA sequence upstream of the ampC gene in an E.
coli isolate from a patient in a hospital in KwaZulu-Natal,
South Africa with increased resistance to cefoxitin to




E. coli NGZ55 was isolated from a patient in a public sector hospital
in Kwazulu-Natal, South Africa in 2000. The identity of the isolate
as E. coli was confirmed using the API20E identification system
(bioMerieux sa, Lyon, France). E. coli ATCC 25922 was used as
the MIC control
Antibiotic susceptibility testing
Susceptibility testing was undertaken using the disc diffusion test
according to CLSI guidelines (2005). MICs values were extra-
polated by the BIOMIC an automated reading system and software
(Giles Scientific, New York), using the following antibiotics:
ampicillin, ampicillin/sulbactam, amoxicillin/clavulanate, ticarcillin,
piperacillin, piperacillin/tazobactam, cephalotin, cefuroxime, cefoxi-
tin, ceftriaxone, cefotaxime, ceftazidime, cefepime, meropenem and
aztreonam (Mast Diagnostics, Merseyside, UK).
p-Iactamase analysis
The 13-lactamases of the E. coli clinical isolate was extracted from a
Nutrient Broth (Biolab, South Africa) culture as described previously
(Livermore and Williams, 1996) Analytical isoelectric focusing (IEF)
was performed in ampholine polyacrylamide gels (pH 3.5 - 9.5;
Amersham Biosciences, Uppsala, Sweden). 13-lactamase bands
were detected with nitrocefin (Oxoid). An isoelectric point marker pi
calibration kit (4.7 to 10.6; BDH, England) was used as the
standard.
peR detection of b1arEM, blaCTX, and blaAmpC genes
Bacterial DNA was prepared by suspending few freshly grown
colonies from an overnight Nutrient Agar (Biolab, South Africa)
culture of E. coli in 50 j,J1 of purified water and heating the cells at
95°C for 5 min. PCR amplifications were then performed in a Gene
Amp PCR System (Applied Biosystems, USA). The primers used
are described in Table 1. PCR conditions for the amplification of
blctrEM was carried out as described by Essack et al (2001). The
amplification mixture for the detection of blacTx and bl8Ampc genes
were each made up to 50 j,J1 and contained 25 j,J1 AmpliTaq Gold
PCR Master Mix (Applied Biosystems, California, USA), purified
water, 10 pmol of each primer (Inqaba Biotechnology, Pretoria,
South Africa) and 2 j,J1 of the template DNA. PCR conditions were
as follows: AmpC: an initial denaturation for 30 s at 94°C, 30 cycles
of 30 s at 94°C, 30 s at 57°C, 1 min at 72°C and a final extension
step of 7 min at 72°C; and CTX: an initial denaturation for 5 min at
94°C, 35 cycles of 1 min at 94°C, 1 min at 56°C, 1 min at 72°C and
a final extension step of 7 min at 72°G. PGR products (5 j,J1) were
analyzed by gel electrophoresis. Gels were stained with ethidium
bromide and photographed using UV illumination. PCR products
were purified and sequenced (Spectrumedix SCE2410 genetic
analysis system, Spectrumedix, Pennsylvania, USA).
RESULTS
The MIC results obtained for E. coli NGZ55 and the
control strain, E. coli ATCC 25922 are shown in Table 2.
E. coli NGZ55 was resistant to amoxicillin/ clavulanate,
ampicillin, cephalotin, cefoxitin and cefuroxime. IEF ana-
lysis revealed the presence of ~-Iactamases with pis of
6.5 and 6.6. PCR and sequencing data showed that the
isolate harboured TEM-1 and CTX-M1. Comparison of
Mocktar et al. 2549
Table 2. MIC (lJg/ml) profiles of E. coli NGZ55 and E. coli ATCC 25922 (control strain).
Isolate AMP PIP AMC TZP CEF CXM FEP FOX CTX CRO CAZ MEM ATM
NGZ55 6 10 >64 4 >128 8 2 >96 1 2 6 0.5 4
ATCC 25922 4 ND 6 1 24 4 <1 2 <0.5 <1 1 <0.5 <2
AMP, ampicillin; PIP, piperacillin; AMC, amoxicillinJclavulanate; TZP, piperacillinJtazobactam; CEF, cephalotln; CXM, cefuroxlme; FEP, cefeplme;
FOX, cefoxitin; CTX, cefotaxime; CRO, ceftriaxone; CAZ, ceftazidime; MEM, meropenem; ATM, aztreonam.
NO = not determined.
Table 3. Mutations in promoter and attenuator regions"
Isolate Mutation
E. coli NGZ55 Extra G between -26 and -25; A(-1 OlC; extra A between +8 and +9;
extra C between +39 and +38; extra C between +54 and +53
'Compared with E. coli K-12 (Caroff et aI., 2000).
the AmpC sequences using Blast 2.0
(http://www.ncbi.nlm.nih.gov/Blast; last accessed June
2006) showed that the sequences corresponded to the
chromosomal AmpC sequences of E. coli.
The E. coli isolates showed changes in the AmpC
promoter region compared to that of E coli K-12. The
changes observed in the promoter and attenuator regions
are shown in Table 3. The optimal distance between the -
10 and-35 Pribnow boxes is 17bp. E. coli NGZ55 had an
additional nucleotide, G, between positions -26 and -25.
Mutations in the -10 box included changes at position -10
and this changed the -10 box from TACAAT to TACCAT
(changes in boldface). Changes upstream of the -35 box
included A(-82)C, T(-47)G, A(-43)C, G(-40)C, A(-39)C
and A(-37)T.
Isolate E. coli NGZ55 in addition showed a further
nucleotide addition, A, between positions +8 and +9.
Changes between the attenuator region and the start
codon included the following: T(+41)G, T(+43)A and
T(+45)G. E. coli NGZ55 also had the following extra
nucleotides: an additional C between positions +39 and
+38 and an additional C between positions +54 and +53.
No SHV-, OXA- and plasmid-mediated AmpC type-~­
lactamases were detected (data not shown).
DISCUSSION
E. coli is an important pathogen that commonly causes
serious infections (Forward et aI., 2001) and therefore,
the emergence of E. coli strains resistant to the cepha-
mycins should be a cause for concern to clinicians
managing infections in both the community and institu-
tional setting. Some of these strains have become
resistant by virtue of their hyperproduction of chromoso-
mally encoded AmpC ~-Iactamases whilst others have
acquired plasmidic ~-Iactamases; most often those
derived from Citrobacter freundii (Clark et aI., 2003).
The chromosomal cephalosporinase gene, ampC, of E.
coli is regulated by a weak promoter and a transcriptional
attenuator. Strains carrying the wild-type gene produce
low basal amounts of AmpC and are inherently
susceptible to ampicillin. Occasionally, this enzyme is
overproduced in E. coli and these strains are resistant to
cefoxitin and have reduced susceptibilities to the newer
~-Iactams such as the oxyiminocephalosporins. Some
hyperproducers also contain more than one copy of
ampC, while others contain mutations in the regulatory
and/or attenuator regions of ampC~ resulting in more
efficient transcription of the structural gene (Nelson and
Gay Elisha, 1999).
AmpC ~-Iactamase production in E. coli is controlled by
a typical E. coli promoter. There is no repressor gene, as
is seen in Enterobacter cloacae and C. freundii. An
analysis of the promoter region in E. coli revealed the
presence of two conserved regions, the -35 box and the -
10 box, also called the Pribnow box. The sequence of the
-35 and -10 hexamers and the interbox distance are
crucial for efficient binding of RNA polymerase, thereby
influencing the level of transcription of the gene (Caroff et
aI., 2000; Forward et aI., 2001; Corvec et aI., 2002). An
interbox distance of 16 bp and the presence of a hairpin
attenuator structure contribute to low-level transcription of
the gene (Corvec et aI., 2002). For most promoters the
degree of homology to the -35 box consensus sequence,
TTGACA, and the -10 box consensus sequence,
TATAAT, is directly related to promoter strength.
Variations in the promoter and attenuator regions of
ampC are a mechanism of hyperproduction of the AmpC
protein that results in resistance or reduced susceptibility
to cefoxitin (Mulvey et aI., 2005). Susceptible strains of E.
coli have an inefficient ampC promoter that differs by
several nucleotides from the strong promoter sequence.
Consequently, very little AmpC ~-Iactamase is produced
(Forward et aI., 2001).
In this study, isolate E. coli NGZ55 had an extra
nucleotide, G, between positions -26 and -25. This
created an optimal distance of 17 bp between the -10 box
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and the -35 box and this has been shown in previous
studies to play a role in promoter strength (Forward et aI.,
2001; Siu et aI., 2003; Mulvey et aI., 2005). This isolate
was resistant to cefoxitin with reduced susceptibility to
ceftazidime and aztreonam. However, this isolate was
susceptible to piperacillin/tazobactam and ampicillin/
sulbactam (results not shown) and this MIC profile is
suggestive of an ESBL-producer. However, PCR and
DNA sequencing studies have shown the presence of
only TEM-1 and CTX-M1 in this isolate. This isolate, in
addition to the extra nucleotide between positions -26
and -25, also had a mutation at position -10 to give a new
-10 box which changed it from TACAAT to TACCAT
(change shown in boldface). It also had nucleotide
insertions in the regions just outside the attenuator region
and this included an extra A between positions +8 and +9
and an extra C between positions +39 and +38.
Sequencing data have also shown an extra nucleotide, C,
between positions +54 and +53 which are situated close
to the ATG start codon. Previous studies (Forward et aI.,
2001) have shown that mutations in the attenuator region
result in increased transcription of the ampC gene.
Conclusion
While chromosomal-mediated resistance might spread
more slowly than mobilized 13-lactamases, it is likely that
with intense antibiotic pressure seen in today's medical
practice that chromosomal-mediated resistance will
become an increasing problem and may further limit our
antibiotic choices (Forward et aI., 2001). Routine
surveillance of sensitivity to cefoxitin in E. coli is thus
advocated.
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25 ~-lactamase profiles of38 inhibitor-resistant Escherichia coli isolates obtained from
26 public hospitals in KwaZulu-Natal, selected on the basis of their resistance profiles to
27 one/more of amoxicillin/clavulanate, ampicillin/ sulbactam and piperacillin/tazobactam
28 were analyzed. Isolates were subjected to iso-electric focusing, plasmid profile
29 determination, PCR of the different ~-lactamase genes and sequencing thereof to detect
30 the possible mechanism/s of inhibitor-resistance. A range of ~-lactamases including two
31 inhibitor-resistant TEM ~-lactamases(TEM-145 and TEM-146), a plasmid-mediated
32 AmpC-type ~-lactamase (CMY-20), OXA-I, TEM-55, SHV-2, CTX-Ml and TEM-l
33 were detected. Diverse ~-lactamase genes and/or enzyme combinations, and plasmid
34 profiles inferred extensive mobilization of resistance genes. Inhibitor resistance could be
35 attributed to a range of mechanisms including but not limited to inhibitor-resistant TEM













48 The rapid increase of ~-lactam resistance amongst members ofthe family
49 Enterobacteriaceae is a major source of concern 1 The increased and repeated use of~-
50 lactam antibiotics has led to them becoming ineffective, mainly as a result of the
51 production of~-Iactamases such as TEM-l and SHY-I, which hydrolyze penicillins and
52 narrow spectrum cephalosporins 2 ,3,4 Escherichia coli which is a common component of
53 the intestinal flora of humans and animals, can cause serious diseases including
54 septicaemia and urinary and wound infections. 5 In clinical isolates ofE. coli, plasmid-
55 mediated TEM-l ~-Iactamase is the most frequently encountered enzyme. This enzyme
56 confers resistance to aminopenicillins and carboxypenicillins without affecting their
57 susceptibility to third generation cephalosporins 2
58 In order to overcome this resistance, two types of ~-lactamswere developed, viz., ~-
59 lactams resistant to hydrolysis such as extended spectrum cephalosporins; and ~-
60 lactamase inhibitors, such as c1avulanic acid, sulbactam and tazobactam.4,6 Although~-
61 lactamase inhibitors have poor antibacterial activities by themselves, they covalently bind
62 to the active sites of class A ~-lactamases and inhibit them. 7
63 However, with increasing use of these antimicrobial agents, resistance again began to
64 emerge. The first TEM-type extended spectrum ~-lactamases (ESBLs) were characterized
65 in 1987 and TEM penicillinases resistant to inhibitors were characterized in the 1990s.8
66 Inhibitor-resistant TEM ~-lactamases(IRTs) have been detected in several members of
67 the Enterobacteriaceae from different countries globally9
68 We investigated ~-Iactamase mediated resistance in E. coli isolates obtained from a
69 surveillance study in 16 demographically representative public hospitals at three levels of
36
70 health care in KwaZulu-Natal. A total of 1270 bacterial isolates were collected; of which
71 300 (23.6%) were E. coli isolates. One hundred and seventy-nine of these isolates were
72 resistant to one of the three antibiotic-inhibitor combinations used in this study; 38
73 isolates were chosen for this study as a representative of particular antibiograms from
74 specific hospitals.
75
76 Materials and Methods
77 Bacterial Strains
78 Thirty-eight E. coli isolates from patients seeking care in public hospitals in KwaZulu-
79 Natal were included in this study (Table 1). Isolates were identified using the API20E
80 identification system (bioMerieux sa, Lyon, France). E. coli ATCC 25922 and E. coli
81 NCTC 50192 served as the quality control for susceptibility testing and plasmid size
82 analysis respectively.
83
84 Antibiotic Susceptibility Testing
85 Susceptibility testing was undertaken by a modification of the Kirby-Bauer disk diffusion
86 method following CLSI10 guidelines using the following antibiotics: ampicillin,
87 piperacillin, ticarcillin, carbenicillin, amoxicillinlclavulanate, ampicillinlsulbactam,
88 piperacillin/tazobactam, cephalotin, cefuroxime, cefepime, cefoxitin, cefotaxime,





93 The ~-lactamases were extracted from overnight Nutrient Broth (Biolab, Johannesburg,
94 South Africa) cultures by the freeze-thaw method. I I Isoelectric focusing (IEF) was
95 performed on ampholine polyacrylamide gels (pH 3.5- 9.5; Amersham Biosciences,
96 Uppsala, Sweden) using an isoelectric point marker pI calibration kit (4.7 to 10.6; BDH,
97 Poole, England) as the standard. ~-lactamase bands were detected with nitrocefin (Oxoid,
98 Basingstoke, England).
99
100 Plasmid profile analysis
101 Plasmid DNA was extracted from overnight Nutrient Broth (Biolab) cultures using the
102 method as described previously.12 Plasmid sizes were calculated using computer software
103 (Syngene-Gene Genius, Bio Imaging Systems, Syngene, Cambridge, United Kingdom).
104
105 PCR detection of blaTEM, blaSHV, blacTx, blacMY. blaoxA and blaAmpc genes
106 Bacterial DNA was prepared by suspending overnight Nutrient Agar (Biolab) in distilled
107 water and heating at 95°C for 5 min. PCR amplifications were then performed in a Gene
108 Amp PCR System (Applied Biosystems, Foster City, California, USA). PCR conditions
109 for the amplification of blaTEM and blaSHV genes,13 blacM/ 4 and blaoxA15 were carried
110 out as described previously. The amplification mixture for the detection of blacTx and
111 blaAmpcgenes were each made up to 50111 and contained 25111 AmpliTaq Gold PCR
112 Master Mix (Applied Biosystems, California, USA), purified water, 10pmol of each
113 primer (Inqaba Biotechnology, Pretoria, South Africa; Table 2) and 2fll of the template
114 DNA. PCR conditions were as follows: CTX: an initial denaturation for 5 min at 94°C 35,
38
115 cycles of Imin at 94°C, Imin at 56°C, I min at nOc and a final extension step of7 min at
116 72°C. PCR products (5111) were analyzed by gel electrophoresis. Gels were stained with
1I 7 ethidium bromide and photographed using UV illumination. PCR products were purified
I 18 and sequenced (Spectrumedix SCE2410 genetic analysis system, Spectrumedix, State
119 College, Pennsylvania, USA). The isolates were also tested for the presence of blaFOx,
120 blaMox, blaBIL, blaLAT, blaAcT, blaAcc and blam-IA (data not shown).
121
122 Results
123 The MIC results are shown in Table 3. From the table it can be seen that 38 (100%), 34
124 (89%) and 26 (68%) of the isolates displayed reduced susceptibility to amoxicillinl
125 clavulanate, ampicillin/sulbactam and piperacillin/tazobactam respectively. All 38
126 isolates also displayed reduced susceptibility to cephalothin. With the exception ofE. coli
127 NGZ55 and E. coli GJC95, all the isolates were resistant to ampicillin, piperacillin,
128 carbenicillin and ticarcillin. The only antibiotic to which all the isolates were sensitive
129 was meropenem. Table 3 summarizes the plasmid profiles and ~-Iactamase characteristics
130 of the isolates. From the table it can be seen that 1-5 plasmids ranging in size from 13 .4kb
131 to 311.1kb were detected in the isolates. No plasmids were detected in isolates ESH31,
132 GJC53, GJC85, GJC95 and ADD66. TEM-I was found in all isolates, whilst TEM-55
133 was found in isolate MDD39. Isolates PMM40 and NWE11 produced the inhibitor-
134 resistant enzymes, TEM-145 and TEM-146 respectively18 A plasmid-mediated ArnpC
135 type ~-Iactamase, CMY-20 was produced by isolates KEH1, KEH32 and KEH4214
136 Isolate GJC33 produced OXA-l whilst 12 of the isolates produced CTX-Ml. SHV-2 was
137 detected in 2 of the isolates.
39
138 Discussion
139 Inhibitor resistance in E. coli may be attributed to: hyperproduction of class C
140 chromosomal ~-lactamase (cephalosporinase), hyperproduction of plasmid-mediated
141 TEM-l or TEM-2, production of an IRT or the production of a relatively inhibitor-
142 resistant OXA-type ~-lactamase.19.20
143 The first amoxicillinlclavulanate-resistant E. coli isolate was noted in 1987 in France.
21
144 Amoxicillin/clavulanate is a ~-lactam ~-Iactamase inhibitor combination that has
145 antibacterial activity against gram positive, gram negative and anaerobic microorganisms.
146 E. coli, one ofthe most common pathogens in community acquired and nosocomial
147 infections, is usually susceptible to amoxicillinlclavulanate. 15 However, with increasing
148 use, resistance to amoxicillin/clavulanic acid appeared, first in E. coli isolates, then in
149 other species of enterobacteria. 19
150 A study by Henquell et al. 2 showed that 40% of E. coli isolates from hospitals and 18% of
151 isolates from private laboratories were resistant to amoxicillin/clavulanate. Other studies
152 carried out in the United States15 and France21 showed that 3% and 5% of theE. coli
153 isolates were resistant to amoxicillinlclavulanate respectively. A recent study in
154 Pakistan22 which investigated the prevalence and antibiotic resistance of urinary tract
155 pathogens showed that 58% of the E. coli isolates were resistant to amoxicillinl
156 clavulanate whilst a study in Tanzania23 which conducted a surveillance of antimicrobial
157 resistance in a tertiary hospital revealed that 28% of the E. coli isolates were resistant to
158 amoxicillin/clavulanate. Two studies conducted in South Mrica26.27 using bacterial
159 cultures obtained from 7 private pathology practices in all the private hospitals in
160 Johannesburg, Cape Town, Durban, Bloemfontein and Pretoria during 2006 and 2007
40
161 showed that 37% and 39% of theE. coli isolates were resistant to amoxicillin/clavulanate
162 respectively. In this study, 59.6% of the E. coli isolates were resistant to
163 amoxicillinlclavulanate. The study by Brink et at. 24 showed significant regional
164 differences in antibiotic susceptibility in resistance patterns in South Mrica and the E.
165 coli isolates from the private hospitals in Durban showed 42% resistance to
166 amoxicillin/clavulanate. There have been no documented reports of amoxicillinl
167 clavulanate resistance amongst E. coli isolates from public sector institutions in South
168 Mrica. The South Mrican, Tanzanian and Pakistani studies only reported
169 amoxicillinlclavulanate resistance but did not investigate mechanisms of resistance.
170 In this study peR and sequencing results showed that all the isolates carried TEM-type ~-
171 lactamases. This is to be expected as one of the mechanisms of ~-Iactam-~-Iactamase
172 mediated resistance in E. coli is TEM hyper-production?
173 Two inhibitor-resistant TEM ~-Iactamases, viz., TEM-145 and TEM-146 were found in
174 isolates PMM40 and NWEll respectively. TEM-145 had 2 substitutions compared with
175 the sequence ofTEM-l, i.e., L221M and R244H whilst TEM-146 had 3 substitutions
176 compared to TEM-l, i.e., T114P, M1821 and R244H. 18 Residue 182 is located just before
177 the a-helix and this is far from the binding site 3 This substitution does not affect the ~-
178 lactamase activity but rather acts as a global stabilizer. 26
179 It has been shown that many inhibitor resistant clinical isolates and laboratory mutants
180 may have emerged as a result of single or multiple mutations in the structural genes of
181 their ~-lactamases6 Substitution of critical residues at positions 69 130 244 and 276, ,
182 have been shown to produce the IRT phenotype by themselves or in combination with
183 other placements. 7,27
41
184 Isolates PMM40 and NWEll displayed resistance to amoxicillin/c1avulanate and
185 ampicillin/sulbactam whilst isolate PMM40 was resistant and isolate NWEl1 displayed
186 intermediate resistance to piperacillin/tazobactam.
187 A plasmid-mediated AmpC-type ~-lactamase, viz., CMY-20, was found in 3 of the
188 isolates. These isolates, viz., KEHl, KEH32 and KEH42 were resistant to all the~-
189 lactamases tested with the exception of meropenem and cefepime. In addition, these 3
190 isolates were also resistant to other antibiotics such as chloramphenicol, gentamicin and
191 trimethoprim/sulfametoxazole (data not shown) CMY-20 belongs to the Citrobacter
192 freundii group and has the following substitutions compared to CMY-2: R125S, R146T
193 and S309N. 14 Bacteria with plasmid-mediated AmpC enzymes are generally resistant to
194 inhibitor combinations, with the possible exception oftazobactam.28 All 3 isolates were
195 resistant to all the antibiotic-inhibitor combinations tested.
196 GJC-33 displayed reduced susceptibility to all three inhibitor combinations. This isolate
197 in addition to harbouring TEM-l, also harboured OXA-l. OXA-type ~-lactamases confer
198 resistance to ampicillin and cephalosporin and they are poorly inhibited by c1avulanic
199 acid
29
and this could have contributed to the inhibitor resistance of this isolate.
200 Isolate NGZ55 was resistant to cefoxitin but only TEM-1 and CTX-Ml was found in this
201 isolate. Analysis (data not shown) of the chromosomal AmpC promoter region of this
202 isolate revealed that there were changes in the promoter region. 3D This isolate had an
203 extra base pair between the -35 and -10 region and this created an optimal distance of 17
204 base pairs in this region. A distance of 16 base pairs leads to low level of transcription of




208 The diversity of enzymes and the high incidence of resistance ofE. coli clinical isolates
209 from public hospitals in KwaZulu-Natal to inhibitor combinations are of great concern
210 and use of these drugs needs to be carefully monitored.
211
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367 Table 1: Epidemiology, phenotypes and ~-lactamase genes ofE. coli isolates collected in
368 2000 from public hospitals in KwaZulu-Natal
369
Isolate Source Plasmid Size(s) pI value(s) ~-lactamase (s)
found
NGZ55 Pus swab 129.21 6.51 TEM-1
84.61 6.6 CTX-M1
GP6 Urine 112.05 6.13 TEM-l
7.93
GP34 Urine 112.05 5.94 TEM-1
7.45
GP45 Pus swab 84.55 5.94 TEM-l
28.39 7.17 SHV-2
GP54 Pus swab- sub 129.00 5.08 TEM-1
cutaneous 36.20 7.22 SHV-2
GP68 Urine 112.05 7.75 TEM-l
54.06
NWEl1 Urine 129.21 6.00 TEM-1
112.2 7.75 TEM-146
ADD66 Urine ND 6.92 TEM-1
PS19 Pus swab- septic 129.21 6.32 TEM-l
wound 7.26 CTX-M1
PS26 Pus swab- septic 171.36 5.57 TEM-l
abdominal wound 97.43 6.2
PS68 Pus swab- cellulitis 148.8 6.23 TEM-l
and blisters 8.11 CTX-M1
GT27 Urine 197.33 6.69 TEM-l
8.68 CTX-M1
GT44 Urine 197.33 7.75 TEM-1
97.33
21.48
ESH18 Urine 148.8 5.55 TEM-1
15.47 7.93 CTX-M1
8.12
ESH31 Urine ND 5.83 TEM-l
6.01
8.48
ESH90 Pus swab 137.77 6.19 TEM-l
8.21
KEHl Peritoneal fluid 148.5 6.00 TEM-l
8.54 CMY-20
KEH32 Pus swab 148.5 5.85 TEM-1
8.75 CMY-20
KEH42 Peritoneal fluid 148.5 6.60 TEM-1
8.39 CMY-20
PMM40 Urine 112.05 6.6 TEM-1
50
8.3 TEM-145
PMM86 Blood 226.56 5.92 TEM-l
97.34 8.21
58.34
MDD38 Urine 109.36 6.65 TEM-l
MDD39 Urine 127.57 6.88 TEM-l
32.32 7.75 TEM-55
EGU4 Pus swab- scrotal 171.36 6.41 TEM-l
abscess 8.3
EGU5 Urine 171.36 6.01 TEM-l
7.75
EGU68 Urine 171.36 6.6 TEM-l
97.43 8.3
GJC5 Pus swab- right ear 2] 1. 76 6.51 TEM-l
8.2




GJC33 Urine 158.82 6.13 TEM-l
6.7 OXA-l
GJC35 Urine 311.0] 6.03 TEM-l




GJC53 Urine ND 6.04 TEM-l
7.55




GJC78 Urine 151.82 6.79 TEM-l
43.73 8.68 CTX-Ml
GJC79 Urine 345.65 6.41 TEM-l
8.49 CTX-Ml
GJC85 Urine ND 6.79 TEM-l
8.35 CTX-Ml
GJC87 Urine 139.42 6.32 TEM-l
8.68 CTX-Ml
GJC9] Urine ]27.39 6.60 TEM-]
31.42 8.68 CTX-Ml
GJC95 unknown ND 6.51 TEM-l
370




373 Table 2: Primers used in PCR studies
374
Primer Primer Sequence Purpose Reference
of primer
COLA 5' -ACGACGCTCGCGCCTTA-3' Amp/Seq 17
COLB 5'-AAGAATCT GCCAGGCGGC-3' Amp/Seq 17
AmpC RI 5' -GTTTGCTGCGTGACGGGCTG -3' Amp/Seq Designed for
this study
AmpC Fl 5'-ACCACGCGAT GCACGATCTG-3' Amp/Seq Designed for
this study
AmpCR2 5'- GATGACA GCAAGGAAAAGCGGAG-3' Amp/Seq Designed for
this study
AmpC F2 5' -GCCGGTAAATCCTGACACCATC-3' Amp/Seq Designed for
this study
CTX-MF 5'-TTTGCGATGTGCAGTACCAGTAA-3' Amp/Seq 16
CTX-MR 5'-CGATATCGTTGGTGGTGCCATA-3' Amp/Seq 16
375






























405 Table 3: MICs (llg/m1) of the E. coli clinical isolates
406
Isolate AMP PIP TIC CAR AMC SAM TZP CEF CXM: FEP FOX CTX CRO CAZ MEM ATM
NGZ55 6 10 4 16 >64 8 4 >128 48 4 >96 1 2 6 0.5 4
GP6 >48 >512 >256 >512 >64 48 6 48 10 <1 8 <0.5 2 6 0.5 6
GP34 >48 512 256 >512 >64 20 >512 24 8 <1 4 <0.5 2 4 0.5 2
GP45 >48 512 >256 >512 >64 12 6 >128 10 1 4 1 4 4 0.5 4
GP54 >48 >512 >256 >512 >64 16 6 >128 10 2 6 4 8 8 <0.5 4
GP68 >48 >512 >256 >512 >64 >48 48 64 10 2 6 <0.5 2 12 0.5 4
NWEll >48 >512 >256 256 >64 >48 20 64 6 2 6 <0.5 <1 4 <0.5 4
ADD66 >48 512 >256 >512 >64 20 4 64 8 2 12 1 <1 4 <0.5 6
PS19 >48 >512 >256 >512 >64 >48 256 >128 10 2 8 1 <1 6 <0.5 4
PS26 >48 >512 >256 >512 >64 >48 48 64 4 1 6 0.5 <1 4 <0.5 <2
PS68 >48 256 >256 >512 >64 10 4 64 6 2 4 0.5 <1 4 <0.5 <2
GT27 >48 >512 >256 >512 >64 >48 48 64 8 4 6 1 <1 4 <0.5 4
GT44 >48 >512 >256 >512 >64 >48 20 48 12 <1 8 1 <1 20 <0.5 >64
53
ESH18 >48 >512 >256 >512 >64 >48 la 16 6 <1 6 0.5 <1 4 <0.5 <2
ESH31 >48 >512 >256 >512 >64 >48 la 64 6 <1 6 0.5 <1 4 <0.5 <2
ESH90 >48 >512 >256 >512 >64 >48 32 64 6 2 8 1 2 6 <0.5 4
> >128
KEH1 >48 >512 >256 >512 >64 >48 >512 >128 96 4 >96 >256 >128 1 >64
>
KEH32 >48 >512 >256 >512 >64 >48 >512 >128 96 4 >96 >256 >128 >128 1 >64
>
KEH42 >48 >512 >256 >512 >64 >48 >512 >128 96 8 >96 >256 >128 >128 1 >64
PMM
40 >48 >512 >256 >512 >64 >48 96 >128 6 2 6 0.5 <I 6 <0.5 2
PMM
86 >48 >512 >256 >512 >64 >48 96 64 4 <1 4 1 <1 4 <0.5 4
MDD
38 >48 >512 >256 >512 >64 >48 48 64 8 <1 6 1 <1 4 <0.5 <2
MDD
39 >48 512 >256 >512 >64 >48 >512 64 6 4 6 <0.5 <1 4 <0.5 <2
EGU4 >48 >512 >256 >512 >64 >48 16 64 6 4 8 1 <1 4 <0.5 4
EGU5 >48 >512 >256 >512 >64 >48 32 64 8 1 8 1 <1 4 <0.5 2
EGU68 >48 512 >256 >512 >64 32 8 64 6 1 6 2 <1 4 <0.5 4
GJC5 >48 >512 >256 32 >64 >48 64 32 la 8 6 2 8 >128 1 >64
GJC31 >48 256 >256 >512 >64 48 64 32 12 2 16 96 32 4 0.5 6
54
GJC33 >48 >512 >256 >512 >64 32 48 24 10 4 4 1 <1 4 <0.5 4
GJC35 >48 512 >256 >512 >64 >48 64 >128 8 <1 6 <0.5 2 4 <0.5 6
>
GJC53 >48 48 >256 >512 >64 8 4 >128 12 1 8 32 6 6 0.5 6
GJC65 >48 >512 >256 >512 >64 32 >512 48 8 1 6 <0.5 <1 4 <0.5 2
>128
GJC78 >48 >512 >256 512 >64 >48 96 48 10 >32 8 <0.5 4 1 >64
GJC79 >48 >512 >256 >512 >64 >48 48 96 10 6 8 <0.5 4 64 0.5 >64
GJC85 >48 >512 >256 >512 >64 >48 >512 64 10 <I 6 <0.5 2 6 0.5 6
GJC87 >48 >512 >256 >512 >64 >48 20 64 8 1 8 <0.5 <1 6 0.5 4
GJC91 >48 >512 >256 >512 >64 32 20 32 6 <1 6 <0.5 <1 4 <0.5 4




410 Abbreviations: AMP, ampicillin; PIP, piperacillin; TIC, ticarcillin; CAR, carbenicillin; AMC, amoxicillinlclavulanate; SAM,
411 ampicillin/ sulbactam; TZP, piperacillinl tazobactam; CEF, cephalotin; CXM, cefuroxime; FEP, cefepime; FOX, cefoxitin; CTX,






The following are significant findings:
• Two novel TEM-derived IRTs, TEM-145 and TEM-146, were detected in isolates
PMM40 and NWE11 respectively.
TEM-145 differed from TEM-1 by the L221M and R2·t4H substitutions.
TEM-146 differed from TEM-l by TlI4P, M1821 and R244H substitutions.
• A novel plasmid-mediated AmpC-type r1-lactamase CMY-20, was detected in 3
isolates, viz., KEHl, KEH32 and KEH42.
This novel differed from CMY-2 by the R125S, R146T and S309N substitutions.
• Changes were detected in the AmpC promoter/attenuator regions of isolate
NGZ55:
Extra G between -26 and -25; A(-IO)C~ extra A betwet:n +8 and +9; extra C
between +39 and +38; extra C between +54 and +53
• OXA-l was detected in 1 isolate, GJC33.
• The ESBL, CTX-M-l was detected in 11 isolates, viz., NGZ55, PS 19, PS68,
GT27, ESH18, GJC33, GJC78, GJC79, GJC85, GJC87 and GJC91.
• An ESBL derived TEM ~-lactamase, TEM-55 was det,~cted in 1 organism, MDD-
39.
57
• The ESBL, SHV-2, was detected in 2 isolates, GP45 and GP54.
• The universal presence ofTEM-1 was evident in all E. coli isolates studied.
• ~-lactamase genes were present in diverse combinations and in isolates with




The following are recommended for further investigation:
• The novel TEM-145, TEM-146 and CMY-20 genes should be cloned into a
recipient so that their unique resistance phenotypes and kinetic characteristics
may be established.
• The identity of undetermined ~-lactamasesevident by IEF and not verified by
PCR should be established.
• The outer membrane protein profiles of the isolates should be established to
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